Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion will be paid up front. The acquisition rests on an ongoing phase I trial of ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion will be paid up front. The acquisition rests on an ongoing phase I trial of ...

With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide.

Below are ten relationship-expert approved Bumble BFF bio examples to help you craft a profile that’ll have your dream crew running over. Meet the Friendship Experts ...

Making friends as an adult is hard. If you’re turning to the apps to help foster some friendship, here are ten of the best Bumble BFF bio examples. Plus, experts share tips on how to make the most of ...

Looking for inspiration to create the best web developer portfolio website? Explore this personal portfolio website designed specifically for modern developers and creatives. Whether you're a ...

Boundless Bio Announces Portfolio Prioritization and Runway ExtensionPortfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, ...

Welcome to Winged Canvas, your Online School of Illustration and Art Nerd Community! 🌟 We're not just a YouTube channel; we're a collective of passionate artists and educators on a mission to ...

Boundless Bio said it would reduce its workforce by about one-third as part of a portfolio prioritization. The clinical-stage oncology company said it had 64 employees as of March 21, which would ...

The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from ...

On May 16, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced a $270 million acquisition of Inozyme Pharma, aiming to expand its rare disease research.